Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	5404.75
Equity-to-Asset	0.84
Interest Coverage	No Debt
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	21.87	Distress Grey Safe
Beneish M-Score	-2.01	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	14.9
	3-Year EBITDA Growth Rate	-2.2
	3-Year EPS without NRI Growth Rate	3.4
	3-Year FCF Growth Rate	-2.2
	3-Year Book Growth Rate	3
	Future 3-5Y EPS without NRI Growth Rate	41.4
	Future 3-5Y Total Revenue Growth Rate	24.15

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	76.45
	9-Day RSI	64.58
	14-Day RSI	60.2
	6-1 Month Momentum %	24.87
	12-1 Month Momentum %	26.95

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.18
	Quick Ratio	5.1
	Cash Ratio	4.23
	Days Inventory	342.06
	Days Sales Outstanding	28.22
	Days Payable	629.98

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	4
	Shareholder Yield %	0.05

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	98.54
	Operating Margin %	23.29
	Net Margin %	22.54
	FCF Margin %	23.85
	ROE %	23.92
	ROA %	19.58
	ROIC %	69.46
	ROC (Joel Greenblatt) %	22858.83
	ROCE %	24.21
	Years of Profitability over Past 10-Year	8

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	31.55
	Forward PE Ratio	46.8
	PE Ratio without NRI	31.55
	Shiller PE Ratio	47.1
	Price-to-Owner-Earnings	44.04
	PEG Ratio	5.84
	PS Ratio	7
	PB Ratio	6.35
	Price-to-Tangible-Book	6.35
	Price-to-Free-Cash-Flow	29.56
	Price-to-Operating-Cash-Flow	29.56
	EV-to-EBIT	24.29
	EV-to-EBITDA	23.96
	EV-to-Revenue	5.66
	EV-to-Forward-Revenue	4.62
	EV-to-FCF	23.69
	Price-to-Projected-FCF	1.51
	Price-to-Median-PS-Value	0.84
	Price-to-Graham-Number	2.98
	Price-to-Net-Current-Asset-Value	8.79
	Price-to-Net-Cash	11.48
	Earnings Yield (Greenblatt) %	4.12
	FCF Yield %	3.59
	Forward Rate of Return (Yacktman) %	6.93

GF Value: $36.89

CORT

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with CORT. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.